



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive
#02-01 Amnios
Singapore 138622

For Immediate Release

Singapore Institute of Advanced Medicine Holdings Ltd. marks a historic milestone as the first listing on the Catalist Board of the SGX-ST in the Year of the Dragon

- Strong support from the investment community with Placement Shares taken up by prominent investors and Public Offer Shares oversubscribed 1.39 times.
- By building a one-stop ambulatory cancer centre with advanced technology, the Group aims to offer early and accurate diagnosis and treatment to cancer patients to help them achieve better outcomes and improve their quality of life.
- The Group is well-positioned to capture the greater demand for cancer treatment options like proton beam therapy in the Asia-Pacific region.

Singapore, 16 February 2024 – Singapore Institute of Advanced Medicine Holdings Ltd. (“**SAM Holdings**” or the “**Company**”, and together with its subsidiaries, the “**Group**”), made its debut on the Catalist Board of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) today under the ticker symbol “9G2”. This marks the first listing on SGX-ST in this auspicious year of the dragon.

Through the initial public offering (“**IPO**”), SAM Holdings has successfully raised S\$26.2 million from the 114.0 million new shares (the “**Invitation Shares**”) offered at S\$0.23 for each share. The 109.1 million Placement Shares was fully subscribed and allocated while the 4.9 million Public Offer Shares was oversubscribed by 1.39 times.

Cancer was one of the leading causes of death in Singapore, accounting for 28.2% of all deaths annually from 2017 to 2021. In fact, according to the World Health Organization, new cancer cases globally are expected to increase to 35 million in 2050, a 77% increase from the estimated 22 million cases in 2022¹. As one of the only few proton therapy service providers in the Asia Pacific region, the Group is well-positioned to capture the greater demand from growing medical tourism in the region. The IPO will provide the Group with access to capital markets along with regional opportunities for inorganic growth and the proceeds from the IPO will be used to finance the acquisition of new equipment and facilities and upgrading of systems, working capital and repayment of bank borrowings.

¹ World Health Organisation: <https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services>



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive
#02-01 Amnios
Singapore 138622

Dr Djeng Shih Kien, the Executive Director and CEO, and founder of SAM Holdings, said, *“It is a great honour to be the first company listed on the SGX-ST in this auspicious year of the dragon. We are overwhelmed by the support and it gives us immense pleasure to see the number of people who share the common vision.*”

As we take our place on the Singapore Exchange, I would like to extend my gratitude to all those who have worked with us tirelessly and supported us in our journey to fight cancer. We will continue to create a synergistic ecosystem of the latest innovations and the brightest minds to push the boundaries in pursuit of the next breakthrough.”

- - End - -





Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive
#02-01 Amnios
Singapore 138622

About Singapore Institute of Advanced Medicine Holdings Ltd. (“SAM Holdings”)

Incorporated in 2011, SAM Holdings is a healthcare service provider using advanced technology for early and accurate diagnosis and offering appropriate treatments to achieve better outcomes and quality of life for our patients. The Group’s services cater to a wide spectrum of diseases and health conditions including, but not limited to, cancer, neurodegenerative and cardiovascular disease detection, and treatment. The Group is primarily engaged in two key business segments: (i) Medical Diagnostics and Treatments; and (ii) Radiation Therapy and Medical Oncology Services.

The goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer. The Group aims to do this by bringing together a dedicated team of professionals and experts from the industry who will empower them to take away the fear of cancer by finding the answers and solutions for the diagnosis, treatment, and ongoing quality of life improvements for cancer patients.

For more information, please visit SAM Holdings’ website at <http://www.advancedmedicine.sg>

**Issued for and on behalf of Singapore Institute of Advanced Medicine Holdings Ltd.
By Financial PR Pte Ltd**

For more information please contact:

Shivam SARAF / Kamal SAMUEL / Urvija DIWAN

Financial PR Pte Ltd

Tel: 6438 2990 / Fax: 6438 0064

E-mail: shivam@financialpr.com.sg / kamal@financialpr.com.sg / urvija@financialpr.com.sg

Disclaimer: This press release is for information only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities or an inducement or recommendation to enter into any investment activity, nor shall any part or all of this press release form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. None of the Company nor any of its subsidiaries, controlling persons, PrimePartners Corporate Finance Pte. Ltd., nor any of their respective directors, officers, partners, employees, agents, representatives or advisers makes any representation or warranty (express or implied) regarding, or assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. Readers should read the final offer document to be registered with the Singapore Exchange Securities Trading Limited acting as agent on behalf of the Monetary Authority of Singapore before making any investment decision. If any reader is in any doubt as to the action he/she/it should take, he/she/it should consult his/her/its legal, financial, tax or other professional adviser(s).



Singapore Institute of Advanced Medicine Holdings Ltd.

1 Biopolis Drive
#02-01 Amnios
Singapore 138622

This press release has been prepared by the Company and reviewed by the Sponsor, PrimePartners Corporate Finance Pte. Ltd., in compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules.

This press release and its contents have been reviewed by the Sponsor, for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr. Mark Liew, Chief Executive Officer and Executive Director, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.